IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease

Summary

This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma. Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9 months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior to the first vaccination.

Timeline

Start

2007-05

Primary completion

2009-08

Completion

2009-08

Drugs

Indications